Literature DB >> 26049704

Influence of urban/rural and coastal/inland environment on the prevalence, phenotype, and clinical course of inflammatory bowel disease patients from northwest of Spain: a cross-sectional study.

Daniel Carpio1, Manuel Barreiro-de Acosta, Ana Echarri, Santos Pereira, Javier Castro, Rocio Ferreiro, Aurelio Lorenzo.   

Abstract

BACKGROUND: Data on the influence of rural/urban and coastal/inland environment on inflammatory bowel disease (IBD) are either conflicting or lacking. Our aim was to analyze whether the environment has any influence on the prevalence, phenotype, and course of IBD.
MATERIALS AND METHODS: We carried out a multicenter retrospective study in 1194 IBD patients from Galicia, Spain. Urban areas were defined as those with over 25,000 inhabitants. Sex, age, family history, smoking, Montreal classification, extraintestinal manifestations, steroid dependence/refractoriness, and treatment were assessed. We used the Student's t-test/Mann-Whitney U tests to compare continuous variables and χ to compare categorical variables. Logistic regression was also used.
RESULTS: Living in urban municipalities was a risk factor for Crohn's disease [relative risk (RR) 1.47; 95% confidence interval (CI) 1.25-1.73; P<0.001]; living in coastal municipalities was a protective factor for ulcerative colitis (RR 0.71; 95% CI 0.60-0.85; P<0.001). Crohn's disease patients living on the coast had more frequent ileocolonic disease and needed immunosuppressives more frequently than inland patients (RR for inland 0.65; 95% CI 0.47-0.90; P=0.008). Urban Crohn's disease patients needed immunosuppressives more frequently than rural patients (RR 1.41; 95% CI 1.04-1.92; P=0.027). Urban ulcerative colitis patients had left-sided colitis less frequently. Coastal ulcerative colitis patients more frequently had extensive colitis.
CONCLUSION: Crohn's disease was found more frequently in urban and coastal areas and ulcerative colitis in inland municipalities. Place of residence may also influence phenotype and clinical course as patients living on the coast have more frequent ileocolonic Crohn's disease phenotype, extensive ulcerative colitis, and greater need for immunosuppressive therapy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26049704     DOI: 10.1097/MEG.0000000000000395

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  6 in total

Review 1.  The epidemiology and risk factors of inflammatory bowel disease.

Authors:  Yulan Ye; Zhi Pang; Weichang Chen; Songwen Ju; Chunli Zhou
Journal:  Int J Clin Exp Med       Date:  2015-12-15

Review 2.  Systematic review: treatment pattern and clinical effectiveness and safety of pharmaceutical therapies for Crohn's disease in Europe.

Authors:  Filippo Lelli; Solomon Nuhoho; Xin Ying Lee; Weiwei Xu
Journal:  Clin Exp Gastroenterol       Date:  2016-10-05

3.  EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain.

Authors:  María Chaparro; Manuel Barreiro-de Acosta; José Manuel Benítez; José Luis Cabriada; María José Casanova; Daniel Ceballos; María Esteve; Hipólito Fernández; Daniel Ginard; Fernando Gomollón; Rufo Lorente; Pilar Nos; Sabino Riestra; Montserrat Rivero; Pilar Robledo; Cristina Rodríguez; Beatriz Sicilia; Emilio Torrella; Ana Garre; Esther García-Esquinas; Fernando Rodríguez-Artalejo; Javier P Gisbert
Journal:  Therap Adv Gastroenterol       Date:  2019-05-21       Impact factor: 4.409

4.  Epidemiologic Characteristics of Patients with Inflammatory Bowel Disease in Kermanshah, Iran.

Authors:  Mehdi Zobeiri; Homayoon Bashiri; Lotfollah Askari; Ali Asghar Keshavars; Ramin Tavvafzadeh; Kiomars Fatahi; Farid Najafi
Journal:  Middle East J Dig Dis       Date:  2017-07

5.  Prevalence of Anal Fistulas in Europe: Systematic Literature Reviews and Population-Based Database Analysis.

Authors:  Damián García-Olmo; Gert Van Assche; Ignacio Tagarro; Mary Carmen Diez; Marie Paule Richard; Javaria Mona Khalid; Marc van Dijk; Dimitri Bennett; Suvi R K Hokkanen; Julián Panés
Journal:  Adv Ther       Date:  2019-10-26       Impact factor: 3.845

6.  Impact of comorbidities on anti-TNFα response and relapse in patients with inflammatory bowel disease: the VERNE study.

Authors:  Ignacio Marin-Jimenez; Guillermo Bastida; Ana Forés; Esther Garcia-Planella; Federico Argüelles-Arias; Pilar Sarasa; Ignacio Tagarro; Alonso Fernández-Nistal; Carmen Montoto; Mariam Aguas; Javier Santos-Fernández; Marta Maia Bosca-Watts; Rocio Ferreiro; Olga Merino; Xavier Aldeguer; Xavier Cortés; Beatriz Sicilia; Francisco Mesonero; Manuel Barreiro-de Acosta
Journal:  BMJ Open Gastroenterol       Date:  2020-03-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.